UBS Group’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

UBS Group’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-125,681	Closed	-$1.26M	–	10364
2023 Q4	$1.26M	Buy	125,681 +123,369	+5,336%	+$560K	﹤0.01%	4294
2023 Q3	$6.66K	Sell	2,312 -424	-15%	-$1.55K	﹤0.01%	7285
2023 Q2	$10.4K	Buy	2,736 +169	+7%	+$473	﹤0.01%	7141
2023 Q1	$4.78K	Sell	2,567 -1,030	-29%	-$2.15K	﹤0.01%	8146
2022 Q4	$8.27K	Sell	3,597 -306	-8%	-$937	﹤0.01%	8791
2022 Q3	$13K	Buy	+3,903	New	+$12.7K	﹤0.01%	8094
2022 Q1	–	Sell	-1,635	Closed	-$10K	–	11165
2021 Q4	$10K	Buy	+1,635	New	+$15.7K	﹤0.01%	8818
2021 Q3	–	Sell	-422	Closed	-$5K	–	10286
2021 Q2	$5K	Buy	+422	New	+$5.65K	﹤0.01%	8591

UBS Group's GRCL Position: Q1 2024 in Review

UBS Group sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 125,681 shares — an estimated $1.26M sold.

UBS Group first reported a position in GRCL in Q2 2021 and held it in 8 quarters. The position peaked at $1.26M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

UBS Group reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
UBS Group sold 125,681 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $1.26M.
UBS Group first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2021 and held it in 8 quarters.
UBS Group's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $1.26M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.